CareDx Acquires Xyn Management to Advance Transplant Quality Management Solutions

On August 30, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that pharmaceutical company CareDx announced the acquisition of biotechnology company XynManagement (Xyn). Specific financial details of the acquisition have not been disclosed.

Following the completion of this acquisition, CareDx and Xyn will further develop transplant quality management solutions to enhance diagnostic and therapeutic efficiency in the field of transplantation.

CareDx, founded in 2000 and headquartered in Brisbane, California, is a leading biotechnology company. The company focuses on providing commercialized, differentiated, high-value healthcare solutions to medical caregivers, offering medical products and testing services for patients before and after transplantation. CareDx’s technology applies modern genomics techniques to the development of molecular diagnostic assays, translating patients’ immune status into clinically actionable information.

CareDx’s AlloMap Molecular Expression Testing (AlloMap), used in the management of heart transplant patients, leverages molecular expression technology that can be applied to post-transplant management for recipients of other organs. CareDx is also exploring the application of gene expression testing to other immune system-related diseases, such as autoimmune and chronic inflammatory conditions.

Xyn, founded in 2012 and headquartered in Texas, USA, is a biotechnology company. The company is dedicated to streamlining transplant quality tracking processes and reducing wait times for patients awaiting transplantation. Xyn’s solutions address the primary challenges faced by transplant centers today.

Xyn offers two unique solutions: XynQAPI and Waitlist Management. XynQAPI enables transplant professionals to assess the risks associated with candidates and donors, track transplant quality in real time, and improve patient outcomes. It streamlines transplant quality tracking and reporting to the Scientific Registry of Transplant Recipients (SRTR), and assigns a dedicated transplant coordinator to each patient. This coordinator maintains regular contact with patients on the waiting list to help them prepare for transplantation and maintain their eligibility. Additionally, XynQAPI compiles and processes data to deliver accurate analytics, saving healthcare professionals’ time and enhancing transplant efficiency.

David Axelrod, CEO of Xyn, stated, “I am pleased to see the collaboration between CareDx and Xyn. We believe that integrating the value of CareDx’s solutions can better improve patient outcomes. Our leadership team, with extensive experience in transplantation, will continue to work with CareDx to develop solutions that enhance the efficiency of transplant quality management.”

CareDx CEO Peter Maag stated, “Xyn’s transplant waitlist management enables CareDx to expand its patient reach into the pre-transplant space. Our organization is committed to improving outcomes for transplant patients. The transplant quality management solution delivers additional benefits that reinforce our leadership position in the transplant field.”

(Compiled by Hu Yifan)